Multicell Techs Inc (MCET)
Multicell Techs Inc is a common stock listing on OTC Markets tied to MultiCell Technologies, Inc., a biopharmaceutical company focused on developing therapeutics and discovery tools for neurological disorders, hepatic disease, cancer, and selected cardiovascular applications. Its pipeline includes MCT-125, a Phase II candidate being studied for primary multiple sclerosis-related fatigue, along with MCT-465 and MCT-485, both of which are at earlier development stages and are being evaluated for cancer-related applications. The company is also developing Ideal BioStent, a bioabsorbable stent for interventional cardiology and peripheral vessel use. MultiCell Technologies has license agreements with Corning Incorporated and Pfizer Inc. The company was previously known as Exten Industries, Inc. and adopted its current name in April 2004. It was founded in 1962 and is based in Woonsocket, Rhode Island.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Analyst Price Target | Analyst Target Upside/Downside | Overall Financial Health | Dividend Yield | Market Cap |
|---|---|---|---|---|---|---|
|
OTC-MCET
|
Not available
|
Not available
|
Not available
|
Fair
|
0.0%
|
5 K
|